Prof. John Michael Varlotto

Marshall Health Network, USA

Email: [email protected]

Qualifications

1989  M.Sc., University of Pittsburgh School of Medical

1985  B.Sc., Washington & Jefferson College

Publications (selected)

1. Tsai, C. J., Sun, A., Bradbury, P. A., et al. (2026). CCTG BR.38: Consolidative use of radiotherapy to block (CURB2) oligoprogression in patients with metastatic non-small-cell lung cancer-A randomized phase III trial. Journal of Clinical Oncology, 44(16_suppl), Article TPS8124.
2. Varlotto, J. M., Xie, Y., Pennell, N., et al. (2025). EA5181: Phase 3 Trial of Concurrent and Consolidative Durvalumab vs Consolidation Durva Alone for Unresectable Stage 3 NSCLC. Journal of Thoracic Oncology, 20(10_suppl), PL03.06.
3. Abdallah, M., Voland, R., Decamp, M., et al. (2024). Evaluation of Anti-Angiogenic Therapy Combined with Immunotherapy and Chemotherapy as a Strategy to Treat Locally Advanced and Metastatic Non-Small-Cell Lung Cancer. Cancers, 16(24), Article 4207.
4. Varlotto, J., Voland, R., Decamp, M., et al. (2025). Role of consolidative thoracic and prophylactic cranial radiation in extensive stage small cell lung cancer in chemo-immunotherapy era. Radiotherapy and Oncology, 202, Article 110619.
5. Nwanwene, K., Voland, R., Flickinger, J. C., et al. (2024). The population-based effects of the FDA's approval of durvalumab as consolidative therapy in patients with locally-advanced non-small cell lung cancer. Journal of Clinical Oncology, 42(16_suppl), Article e20086.
6. Nwanwene, K., Voland, R., Khatri, J., et al. (2023). Lymphatic Vascular Invasion: Diagnostic Variability and Overall Survival Impact on Patients Undergoing Surgical Resection of NSCLC. Journal of Thoracic Oncology, 18(11_suppl), S553.
7. Khatri, J. K., Voland, R., Flickinger, J. C., et al. (2023). Role of consolidative thoracic and prophylactic cranial radiation in extensive stage small cell lung cancer in chemo-immunotherapy era. Journal of Clinical Oncology, 41(16_suppl), 8595.
8. Varlotto, J. M., & Cardarelli, G. A. (2023). Recent advances in cervical cancer radiotherapy. Frontiers in Oncology, 13, Article 1144797.
9. Varlotto, J. M., Sun, Z., Ky, B., et al. (2022). A Review of Concurrent Chemo/Radiation, Immunotherapy, Radiation Planning, and Biomarkers for Locally Advanced Non-small Cell Lung Cancer and Their Role in the Development of ECOG-ACRIN EA5181. Clinical Lung Cancer, 23(7), 547–560.
10. Valluri, A. P., Voland, R., Varlotto, J. M., et al. (2022). The age-adjusted rates and treatment of typical carcinoid tumors of the lung. Journal of Clinical Oncology, 40(16_suppl), 20507.
11. Varlotto, J. M., Bosetti, C., Bronson, D., et al. (2022). Meta-analysis of rates and causes of local recurrence in surgically-resected NSCLC and differences in recurrence and survival between Asian and non-Asian populations. Journal of Clinical Oncology, 40(16_suppl), Article e20579.
12. Varlotto, J., Wang, Y., Sun, Z., et al. (2021). The Association of Bevacizumab with a Decreased Risk of Brain Metastases in ECOG-ACRIN E1505 in Completely Resected Stage IB-IIIA NSCLC. Journal of Thoracic Oncology, 16(10_suppl), FP01.01.
13. Varlotto, J. M., Sun, Z., Ramalingam, S. S., et al. (2021). Randomized phase III Trial of MEDI4736 (durvalumab) as concurrent and consolidative therapy or consolidative therapy alone for unresectable stage 3 NSCLC: A trial of the ECOG-ACRIN Cancer Research Group (EA5181). Journal of Clinical Oncology, 39(15_suppl), Article TPS8584.
14. Varlotto, J. M., Sun, Z., Ky, B., et al. (2021). A Review of Immunotherapy for Stage III and Metastatic Non-Small Cell Lung Cancer and the Rationale for the ECOG-ACRIN EA5181 Study. The Oncologist, 26(6), 523–532.
15. Varlotto, J., Hebert, C., Griffin, M., et al. (2021). Factors Associated with the Diagnosis of Lymphatic Vascular Invasion and its Impact on Prognosis. Journal of Thoracic Oncology, 16(3_suppl), S283.
16. Varlotto, J. M., Voland, R., DeCamp, M. M., et al. (2020). The rates of second lung cancers and the survival of surgically-resected second primary lung cancers in patients undergoing resection of an initial primary lung cancer. Lung Cancer, 147, 115–122.
17. Varlotto, J. M., Emmerick, I., Voland, R., et al. (2020). The Incidence of Node-Positive Non-small-Cell Lung Cancer Undergoing Sublobar Resection and the Role of Radiation in Its Management. Frontiers in Oncology, 10, Article 417.
18. Hebert, C., Emmerick, I. M., Voland, R., et al. (2020). The variance of lymphatic vascular invasion (LVI) diagnosis and its impact on overall survival(OS) independent of node stage in patients undergoing surgical resection on NSCLC. Journal of Clinical Oncology, 38(15_suppl), Article e21060.
19. Alcocer, V. M., Rassaei, N., Febres-Aldana, C., et al. (2020). STAS Tumor Status is a Reproducible Prognosticator Among Practicing Pathologists. Laboratory Investigation, 100(Suppl. 1), 1881.
20. Alcocer, V. M., Rassaei, N., Febres-Aldana, C., et al. (2020). STAS Tumor Status is a Reproducible Prognosticator Among Practicing Pathologists. Modern Pathology, 33(Suppl. 2), 1881.

Profile Details

https://www.marshallhealth.org/find-a-provider/provider-details/?ID=673
https://scholar.google.com/citations?user=QzrvN6EAAAAJ&hl=en
https://www.researchgate.net/profile/John-Varlotto

WOS ResearcherID: DXT-6686-2022